Panitumumab is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is primarily used in cancer therapy, particularly for the treatment of metastatic colorectal cancer. By binding to EGFR, panitumumab inhibits the receptor's activation and downstream signaling pathways, which are crucial for cancer cell proliferation and survival.
